Prostate Specific Antigen (PSA) Blood Test

What Does This Test Measure?

PSA is a protein produced by prostate epithelial cells. It is the primary screening biomarker for prostate cancer, though it is organ-specific, not cancer-specific; PSA can be elevated by benign conditions (BPH, prostatitis) as well as cancer.

Why Your Doctor Ordered This Test

Doctors order a PSA test in several distinct clinical contexts. The most common is screening for prostate cancer in men who have no symptoms, typically as part of a shared decision-making process starting at age 50 (or age 45 for those at higher risk, such as African American men and those with a first-degree relative diagnosed with prostate cancer before age 65). The test is often paired with a digital rectal exam (DRE); a suspicious nodule on DRE prompts a PSA regardless of age. When lower urinary tract symptoms emerge (weak urine stream, hesitancy, nocturia, or a sensation of incomplete emptying) physicians use PSA to help distinguish benign prostatic hyperplasia (BPH) from malignancy. In men with bone pain or unexplained weight loss, an elevated PSA can point toward metastatic prostate cancer as the source. In all screening scenarios, the doctor aims to detect clinically significant cancer early, when it is still organ-confined and curable, while avoiding needless biopsy for indolent disease.

Once a prostate cancer diagnosis is established, PSA becomes a vital monitoring tool. Men on active surveillance undergo repeated PSA measurements every 3–6 months, often combined with free PSA and PSA density (total PSA divided by prostate volume in cubic centimeters). A PSA doubling time shorter than 3 years signals that the cancer may be progressing, prompting re-biopsy. After curative treatment, PSA is used to verify success: following radical prostatectomy the level should fall to an undetectable level (typically <0.1 ng/mL) within 6–8 weeks. Any persistent or rising value indicates residual or recurrent disease, known as biochemical recurrence. After radiation therapy, PSA is monitored for a nadir (usually <1 ng/mL); a rise of 2 ng/mL above that nadir meets the Phoenix definition of recurrence and may trigger salvage therapy. In advanced disease, serial PSA trends help gauge response to androgen deprivation therapy, with a decline of more than 50% at 12 weeks signaling hormone sensitivity.

What High Prostate Specific Antigen Means

High PSA: prostate cancer (elevated PSA is the most common presentation of early prostate cancer, though many elevations are benign), benign prostatic hyperplasia (BPH, very common with aging), prostatitis (acute or chronic, can cause dramatic PSA elevation, up to 50–100+; PSA declines with antibiotic treatment), recent ejaculation, vigorous exercise (cycling), prostate manipulation (DRE, cystoscopy, biopsy; PSA may remain elevated for weeks post-biopsy), and urinary retention with catheterization.

What Low Prostate Specific Antigen Means

Low PSA (<1–2 ng/mL): normal and desirable. In treated prostate cancer: PSA should fall to undetectable after radical prostatectomy (persistent or rising PSA indicates residual or recurrent disease). After radiation, PSA nadir is typically <1.0 ng/mL; a rise of ≥2 ng/mL above nadir indicates recurrence.

How to Prepare and What Affects the Result

Patients should avoid ejaculation for at least 48 hours before a PSA blood draw, because seminal fluid release can cause a transient rise of up to 0.5–1.0 ng/mL. Vigorous exercise, particularly cycling that puts prolonged pressure on the perineum, may also spuriously elevate the result and should be avoided for 24–48 hours prior. The test does not require fasting, but if other tests such as glucose or lipids are being drawn simultaneously, the typical 8–12 hour fast remains appropriate. Certain medications profoundly affect PSA readings. Finasteride and dutasteride, 5-alpha-reductase inhibitors used for BPH or hair loss, lower total PSA by roughly 50% after 6–12 months of use; in a man taking one of these drugs, the true PSA is approximately double the measured value, and any confirmed rise while on a stable dose is still suspicious. Testosterone replacement therapy can increase PSA, while some herbal supplements like saw palmetto may have a minor lowering effect. Prostate manipulations such as cystoscopy, prostate biopsy, or catheter insertion can cause PSA to spike for several weeks; a recent biopsy can keep PSA elevated for 4–6 weeks. Acute urinary tract infections or prostatitis push PSA sharply upward, and blood should be drawn only after the infection has fully resolved, often 4–6 weeks later. The blood sample is a standard serum tube, stable at room temperature for 24 hours, and does not require special handling.

Common Misinterpretations

A common error is to assume that any PSA above 4.0 ng/mL means prostate cancer. In reality, most men with mildly elevated PSA (4–10 ng/mL) do not have cancer; benign prostatic hyperplasia and prostatitis account for the majority of such elevations. Ignoring age-specific thresholds is another pitfall. For a 45-year-old, a PSA of 3.0 ng/mL is more concerning than the same value in a 70-year-old with a large prostate. Clinicians who fail to calculate free PSA percentage when total PSA sits in the 4–10 ng/mL gray zone miss key risk information: a free PSA below 10% carries a roughly 50% chance of cancer on biopsy, while a free PSA above 25% suggests only a 5–8% risk. Similarly, omitting PSA density, total PSA divided by prostate volume on imaging, can lead to missed diagnoses, as a high density (>0.15 ng/mL/cm³) points to cancer even when the absolute PSA is unremarkable.

Medication-related misinterpretations are frequent. Men taking finasteride or dutasteride may have a PSA of 2.0 ng/mL, appearing normal, but the adjusted value is closer to 4.0 ng/mL and requires investigation. Failing to double the PSA in these patients can delay cancer diagnosis. Transient spikes from ejaculation, cycling, or a recent urinary tract infection are often overinterpreted as evidence of malignancy; a repeat test after 4–6 weeks of abstention from possible triggers frequently returns to baseline. After radiation therapy, a temporary PSA bounce (an increase of 0.1–0.5 ng/mL, then a spontaneous decline) can occur 12–36 months post-treatment and is not a sign of recurrence. Mislabeling this benign bounce as biochemical failure leads to unnecessary anxiety and additional procedures. Finally, an 'undetectable' result after prostatectomy must be interpreted with the assay’s sensitivity in mind; ultra-sensitive tests can detect PSA levels of 0.01 ng/mL, and a measurable but stable low value may not require salvage treatment.

Frequently Asked Questions

What is a normal PSA level by age?

Age-specific upper limits are generally <2.5 ng/mL for men 40–49, <3.5 for 50–59, <4.5 for 60–69, and <6.5 for 70–79. These values are not absolute; some labs use a fixed threshold of 4.0 ng/mL. A value within the age-adjusted range does not guarantee absence of cancer, and many elevations are from benign enlargement. Trends over time and free PSA ratio provide critical nuance.

What can cause a false high PSA reading?

Many non-cancer factors elevate PSA. Ejaculation within 48 hours can transiently increase levels by up to 0.5–1.0 ng/mL. Vigorous cycling, acute prostatitis, and urinary tract infections can push PSA above 10 ng/mL, sometimes reaching 50–100 ng/mL. Prostate biopsy, cystoscopy, and catheterization keep PSA elevated for 4–6 weeks. Even a digital rectal exam may cause a minor bump, though modern evidence suggests a clinically insignificant change. A repeat test after abstaining from triggers for 4–6 weeks often clarifies whether an elevation is real or spurious.

What does a high PSA and low free PSA mean?

When total PSA falls between 4 and 10 ng/mL, the free-to-total PSA ratio helps estimate cancer risk. A free PSA percentage below 10% is associated with a roughly 50% probability of prostate cancer on biopsy, whereas a value above 25% suggests a less than 10% chance, favoring benign prostatic hyperplasia. The ratio is less informative at very high total PSA levels. The combination of a high total PSA and a low free PSA makes a urologist more likely to recommend a prostate biopsy.

Why is PSA monitored after prostate removal?

Following radical prostatectomy, all prostate tissue should be gone, so PSA levels are expected to become undetectable (typically <0.1 ng/mL) within 6–8 weeks. Any persistent or subsequently rising PSA, even at very low levels, indicates residual or recurrent cancer, a condition called biochemical recurrence. Serial PSA measurements allow early detection of recurrence, often months or years before it becomes visible on imaging, and guide decisions about salvage radiation or hormone therapy.

Can medications lower PSA?

Yes. Finasteride and dutasteride, 5-alpha-reductase inhibitors used for benign prostatic hyperplasia and male-pattern hair loss, lower serum PSA by approximately 50% after 6–12 months of therapy. Clinicians must double the measured value to estimate the true PSA. Even after adjustment, any confirmed rise while on a stable dose remains concerning. Other medications, including some herbal products like saw palmetto, may have a mild lowering effect, but the evidence is weaker and not routinely used for risk adjustment.

Related Markers: Read Together for Full Context

BloodWorker reads lab values together, not in isolation. These related markers provide essential context for interpreting your Prostate Specific Antigen result: